Loading…

Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type‑I Diabetes

The study summarizes the development of an orally active nanoformulation of a potent but one of the least explored molecules, lisofylline (LSF), in type 1 diabetes (T1D). LSF undergoes rapid metabolism, resulting in poor oral bioavailability and short half-life. In this work, to improve its pharmaco...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2019-12, Vol.16 (12), p.4954-4967
Main Authors: Italiya, Kishan S, Basak, Moumita, Mazumdar, Samrat, Sahel, Deepak K, Shrivastava, Richa, Chitkara, Deepak, Mittal, Anupama
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093
cites cdi_FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093
container_end_page 4967
container_issue 12
container_start_page 4954
container_title Molecular pharmaceutics
container_volume 16
creator Italiya, Kishan S
Basak, Moumita
Mazumdar, Samrat
Sahel, Deepak K
Shrivastava, Richa
Chitkara, Deepak
Mittal, Anupama
description The study summarizes the development of an orally active nanoformulation of a potent but one of the least explored molecules, lisofylline (LSF), in type 1 diabetes (T1D). LSF undergoes rapid metabolism, resulting in poor oral bioavailability and short half-life. In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF–linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF–LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and N agg: 14.82 at 10 cmc] of methoxypoly­(ethylene glycol)-b-poly­(carbonate-co-l-lactide) (mPEG-b-P­(CB-co-LA)) block copolymer. LSF–LA PLM was found to be equally effective as the LSF–LA prodrug in cell culture studies in insulin-secreting MIN6 cells and showed excellent stability in simulating biological fluids and plasma. PK of LSF–LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism. Further, LSF–LA PLM showed a significant reduction in fasting glucose levels and increase in insulin levels by intraperitoneal as well oral routes in a streptozotocin (STZ)-induced T1D rat model. Production of inflammatory cytokines (TNF-α and IFN-γ) and different biochemical markers for liver and kidney functions were much reduced in diabetic animals after treatment with LSF–LA PLM. LSF–LA PLM-treated pancreatic sections showed minimal infiltration of CD4+ and CD8+ T-cells as indicated by hematoxylin/eosin staining and immunohistochemical analysis.
doi_str_mv 10.1021/acs.molpharmaceut.9b00833
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2309473067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2309473067</sourcerecordid><originalsourceid>FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093</originalsourceid><addsrcrecordid>eNqNkD1PwzAQhiMEElD4D2ZjSbHjOB8jlAKVijq0zNbFOYORExc7RcrGyshf5JeQUoTExnQn3fu80j1RdMbomNGEXYAK48bZ9RP4BhRuunFZUVpwvhcdMZHyuOBlsv-7F-lhdBzCM6VJKhJ-FL0vFVioLJIlWh1fhoBNZU37SO6NQmvBk2UfOmyIdp5M2ydoFdZk4cGSK-PgFcyAG2u6nkBbk6nWRoHqidNkboLTvR3a8JteeYSuwbbbHlf9Gj_fPmbk2kCFHYaT6ECDDXj6M0fRw810NbmL54vb2eRyHgNPaRfnGWUpMhSUFaxmtS4U5IyVmaAiExwEozlPa86ZyqscGfAsgUrUSaogU7Tko-h817v27mWDoZONCd-vtug2QSaclmnOaZYP0XIXVd6F4FHLtTcN-F4yKrf65aBf_tEvf_QPrNix28iz2_h2eOof3BfTo5MI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309473067</pqid></control><display><type>article</type><title>Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type‑I Diabetes</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Italiya, Kishan S ; Basak, Moumita ; Mazumdar, Samrat ; Sahel, Deepak K ; Shrivastava, Richa ; Chitkara, Deepak ; Mittal, Anupama</creator><creatorcontrib>Italiya, Kishan S ; Basak, Moumita ; Mazumdar, Samrat ; Sahel, Deepak K ; Shrivastava, Richa ; Chitkara, Deepak ; Mittal, Anupama</creatorcontrib><description>The study summarizes the development of an orally active nanoformulation of a potent but one of the least explored molecules, lisofylline (LSF), in type 1 diabetes (T1D). LSF undergoes rapid metabolism, resulting in poor oral bioavailability and short half-life. In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF–linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF–LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and N agg: 14.82 at 10 cmc] of methoxypoly­(ethylene glycol)-b-poly­(carbonate-co-l-lactide) (mPEG-b-P­(CB-co-LA)) block copolymer. LSF–LA PLM was found to be equally effective as the LSF–LA prodrug in cell culture studies in insulin-secreting MIN6 cells and showed excellent stability in simulating biological fluids and plasma. PK of LSF–LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism. Further, LSF–LA PLM showed a significant reduction in fasting glucose levels and increase in insulin levels by intraperitoneal as well oral routes in a streptozotocin (STZ)-induced T1D rat model. Production of inflammatory cytokines (TNF-α and IFN-γ) and different biochemical markers for liver and kidney functions were much reduced in diabetic animals after treatment with LSF–LA PLM. LSF–LA PLM-treated pancreatic sections showed minimal infiltration of CD4+ and CD8+ T-cells as indicated by hematoxylin/eosin staining and immunohistochemical analysis.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.9b00833</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Molecular pharmaceutics, 2019-12, Vol.16 (12), p.4954-4967</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093</citedby><cites>FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093</cites><orcidid>0000-0003-3344-9579 ; 0000-0003-4174-7664</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Italiya, Kishan S</creatorcontrib><creatorcontrib>Basak, Moumita</creatorcontrib><creatorcontrib>Mazumdar, Samrat</creatorcontrib><creatorcontrib>Sahel, Deepak K</creatorcontrib><creatorcontrib>Shrivastava, Richa</creatorcontrib><creatorcontrib>Chitkara, Deepak</creatorcontrib><creatorcontrib>Mittal, Anupama</creatorcontrib><title>Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type‑I Diabetes</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>The study summarizes the development of an orally active nanoformulation of a potent but one of the least explored molecules, lisofylline (LSF), in type 1 diabetes (T1D). LSF undergoes rapid metabolism, resulting in poor oral bioavailability and short half-life. In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF–linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF–LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and N agg: 14.82 at 10 cmc] of methoxypoly­(ethylene glycol)-b-poly­(carbonate-co-l-lactide) (mPEG-b-P­(CB-co-LA)) block copolymer. LSF–LA PLM was found to be equally effective as the LSF–LA prodrug in cell culture studies in insulin-secreting MIN6 cells and showed excellent stability in simulating biological fluids and plasma. PK of LSF–LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism. Further, LSF–LA PLM showed a significant reduction in fasting glucose levels and increase in insulin levels by intraperitoneal as well oral routes in a streptozotocin (STZ)-induced T1D rat model. Production of inflammatory cytokines (TNF-α and IFN-γ) and different biochemical markers for liver and kidney functions were much reduced in diabetic animals after treatment with LSF–LA PLM. LSF–LA PLM-treated pancreatic sections showed minimal infiltration of CD4+ and CD8+ T-cells as indicated by hematoxylin/eosin staining and immunohistochemical analysis.</description><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkD1PwzAQhiMEElD4D2ZjSbHjOB8jlAKVijq0zNbFOYORExc7RcrGyshf5JeQUoTExnQn3fu80j1RdMbomNGEXYAK48bZ9RP4BhRuunFZUVpwvhcdMZHyuOBlsv-7F-lhdBzCM6VJKhJ-FL0vFVioLJIlWh1fhoBNZU37SO6NQmvBk2UfOmyIdp5M2ydoFdZk4cGSK-PgFcyAG2u6nkBbk6nWRoHqidNkboLTvR3a8JteeYSuwbbbHlf9Gj_fPmbk2kCFHYaT6ECDDXj6M0fRw810NbmL54vb2eRyHgNPaRfnGWUpMhSUFaxmtS4U5IyVmaAiExwEozlPa86ZyqscGfAsgUrUSaogU7Tko-h817v27mWDoZONCd-vtug2QSaclmnOaZYP0XIXVd6F4FHLtTcN-F4yKrf65aBf_tEvf_QPrNix28iz2_h2eOof3BfTo5MI</recordid><startdate>20191202</startdate><enddate>20191202</enddate><creator>Italiya, Kishan S</creator><creator>Basak, Moumita</creator><creator>Mazumdar, Samrat</creator><creator>Sahel, Deepak K</creator><creator>Shrivastava, Richa</creator><creator>Chitkara, Deepak</creator><creator>Mittal, Anupama</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3344-9579</orcidid><orcidid>https://orcid.org/0000-0003-4174-7664</orcidid></search><sort><creationdate>20191202</creationdate><title>Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type‑I Diabetes</title><author>Italiya, Kishan S ; Basak, Moumita ; Mazumdar, Samrat ; Sahel, Deepak K ; Shrivastava, Richa ; Chitkara, Deepak ; Mittal, Anupama</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Italiya, Kishan S</creatorcontrib><creatorcontrib>Basak, Moumita</creatorcontrib><creatorcontrib>Mazumdar, Samrat</creatorcontrib><creatorcontrib>Sahel, Deepak K</creatorcontrib><creatorcontrib>Shrivastava, Richa</creatorcontrib><creatorcontrib>Chitkara, Deepak</creatorcontrib><creatorcontrib>Mittal, Anupama</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Italiya, Kishan S</au><au>Basak, Moumita</au><au>Mazumdar, Samrat</au><au>Sahel, Deepak K</au><au>Shrivastava, Richa</au><au>Chitkara, Deepak</au><au>Mittal, Anupama</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type‑I Diabetes</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2019-12-02</date><risdate>2019</risdate><volume>16</volume><issue>12</issue><spage>4954</spage><epage>4967</epage><pages>4954-4967</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>The study summarizes the development of an orally active nanoformulation of a potent but one of the least explored molecules, lisofylline (LSF), in type 1 diabetes (T1D). LSF undergoes rapid metabolism, resulting in poor oral bioavailability and short half-life. In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF–linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF–LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and N agg: 14.82 at 10 cmc] of methoxypoly­(ethylene glycol)-b-poly­(carbonate-co-l-lactide) (mPEG-b-P­(CB-co-LA)) block copolymer. LSF–LA PLM was found to be equally effective as the LSF–LA prodrug in cell culture studies in insulin-secreting MIN6 cells and showed excellent stability in simulating biological fluids and plasma. PK of LSF–LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism. Further, LSF–LA PLM showed a significant reduction in fasting glucose levels and increase in insulin levels by intraperitoneal as well oral routes in a streptozotocin (STZ)-induced T1D rat model. Production of inflammatory cytokines (TNF-α and IFN-γ) and different biochemical markers for liver and kidney functions were much reduced in diabetic animals after treatment with LSF–LA PLM. LSF–LA PLM-treated pancreatic sections showed minimal infiltration of CD4+ and CD8+ T-cells as indicated by hematoxylin/eosin staining and immunohistochemical analysis.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.molpharmaceut.9b00833</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-3344-9579</orcidid><orcidid>https://orcid.org/0000-0003-4174-7664</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1543-8384
ispartof Molecular pharmaceutics, 2019-12, Vol.16 (12), p.4954-4967
issn 1543-8384
1543-8392
language eng
recordid cdi_proquest_miscellaneous_2309473067
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
title Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type‑I Diabetes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T02%3A42%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scalable%20Self-Assembling%20Micellar%20System%20for%20Enhanced%20Oral%20Bioavailability%20and%20Efficacy%20of%20Lisofylline%20for%20Treatment%20of%20Type%E2%80%91I%20Diabetes&rft.jtitle=Molecular%20pharmaceutics&rft.au=Italiya,%20Kishan%20S&rft.date=2019-12-02&rft.volume=16&rft.issue=12&rft.spage=4954&rft.epage=4967&rft.pages=4954-4967&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.9b00833&rft_dat=%3Cproquest_cross%3E2309473067%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a340t-76014e1e50181d1df8ca71196505653a510734d331c7b7e1a362ab5d24ca6c093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2309473067&rft_id=info:pmid/&rfr_iscdi=true